Pazopanib vs Sunitinib: — Which Drug Suits You?

Almost certainly not. The two drugs show similar tumour control in head-to-head trial data, so the prescription is most likely based on your liver function tests, your tolerance for fatigue, your dosing preference, or another clinical factor — not on one drug being more powerful for your specific cancer. Ask your oncologist which factors they weighed. That answer helps you understand the plan and lets you flag it if something changes, such as your liver results or energy levels.

Yes, and it is one of the most practically important differences. Hand-foot syndrome — redness, peeling and pain on the palms and soles — is reported more frequently with sunitinib, and can be severe enough to make walking painful. Pazopanib causes it less often. If you have a physically active job, existing foot problems, or are caring for a young child at home, that difference is worth raising with your team when the choice is being discussed.

Your oncologist will assess this before starting either drug, because pazopanib in particular requires close liver monitoring throughout treatment. A mildly raised result at baseline does not automatically rule pazopanib out, but it changes how frequently you are monitored and may shift the balance toward sunitinib. Do not start either drug or adjust your dose on the basis of a blood test alone — that decision belongs with your treating team, who will weigh the liver result against everything else.

Switching is possible and does happen. If you have a significant liver reaction on pazopanib, sunitinib may be considered, and vice versa if you are struggling with fatigue or blood count effects on sunitinib. The decision depends on whether the drug was working, how severe the reaction was, and whether any contraindication to the second drug exists. Dose reduction is usually tried before switching. Report side effects early — early reporting is what keeps more options available.

Generic versions of both pazopanib and sunitinib are available in India, and the cost is substantially lower than the original branded versions. The exact cost varies by manufacturer, city, and whether you are accessing any patient assistance programmes. A specific price is not quoted here because it changes and varies significantly between centres. Ask your oncologist or the hospital pharmacist which formulations are currently available and whether any support schemes apply to your situation.

That depends on which drug is prescribed. Sunitinib is typically given on a 4-weeks-on, 2-weeks-off schedule, which gives a planned recovery window each cycle — many patients find their energy and blood counts partially recover during that gap. Pazopanib is taken every day continuously, with no scheduled break. Both drugs are continued as long as they are working and you are tolerating them, and your oncologist reviews that decision regularly based on scans and blood tests.